CJM112: Clinical Trials

6 trials of CJM112, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 23Completed 3

Follow CJM112: new trials by email Literature Review of CJM112 trials Research Report on CJM112

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
PDR001, CJM112, LCL161 - Multiple Myeloma
Phase 1CompletedNovartis Pharmaceuticals262017-12-182022-02-09
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
CJM112, Placebo to CJM112 - Asthma
Phase 2CompletedNovartis Pharmaceuticals1182017-11-062021-10-08
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
CJM112, Placebo - Acne Vulgaris
Phase 2CompletedNovartis Pharmaceuticals522016-12-222022-07-12
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
PDR001, ACZ885, CJM112 - Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Phase 1CompletedNovartis Pharmaceuticals2832016-08-232022-03-29
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
CJM112, Placebo - Hidradenitis Suppurativa (Acne Inversa)
Phase 2CompletedNovartis Pharmaceuticals662015-04-132022-07-13
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
CJM112, Secukinumab, Placebo - Chronic Plaque-type Psoriasis
Phase 1CompletedNovartis Pharmaceuticals952013-06-012020-12-11

Conditions studied

Acne Vulgaris (1)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma of Lung (1)  ·  Asthma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Ductal (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Dyspnea (1)  ·  Hematologic Diseases (1)  ·  Hidradenitis Suppurativa (1)  ·  Intestinal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Multiple Myeloma (1)

Sponsors

Novartis Pharmaceuticals (6)

Countries

United States (6)  ·  Germany (4)  ·  Belgium (2)  ·  Denmark (2)  ·  France (2)  ·  Israel (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Argentina (1)  ·  Canada (1)  ·  Singapore (1)  ·  Slovakia (1)  ·  Switzerland (1)  ·  Taiwan (1)

Top investigators

Christian Vestergaard (1)  ·  Christos C Zouboulis (1)  ·  E P Prens (1)  ·  Falk G Bechara (1)  ·  Gregor Jemec (1)  ·  Jan Mekkes (1)  ·  Lars French (1)  ·  R Hunger (1)  ·  Sylke Schneider-Burrus (1)

NIH funding

2016 (1)